WALTHAM, Mass.--(BUSINESS WIRE)--NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it has formed a scientific advisory board of international experts to help guide the scientific, clinical and market development of its diabetic peripheral neuropathy (DPN) test. The device is a modified version of the Company’s well established NC-stat® nerve conduction study (NCS) system. It is designed to quickly, accurately, and cost-effectively measure sural nerve conduction velocity, a well established quantitative biomarker for DPN, thereby providing the opportunity for earlier and better targeted clinical intervention.
